Related Experiment Video
Updated: Dec 23, 2025
Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts
Published on: April 26, 2018
Identification of 2-Fluoropalmitic Acid as a Potential Therapeutic Agent Against Glioblastoma
Shabierjiang Jiapaer1, Takuya Furuta2, Yu Dong3
1Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Background:
Glioblastomas (GBMs) are aggressive malignant brain tumors. Although chemotherapy with temozolomide (TMZ) can extend patient survival, most patients eventually demonstrate resistance. Therefore, novel therapeutic agents that overcome TMZ chemoresistance are required to improve patient outcomes.
Purpose:
Drug screening is an efficient method to find new therapeutic agents from existing drugs. In this study, we explored a novel anti-glioma agent by drug screening and analyzed its function with respect to GBM treatment for future clinical applications.
Methods:
Drug libraries containing 1,301 diverse chemical compounds were screened against two glioma stem cell (GSC) lines for drug candidate selection. The effect of selected agents on GSCs and glioma was estimated through viability, proliferation, sphere formation, and invasion assays. Combination therapy was performed to assess its ability to enhance TMZ cytotoxicity against GBM. To clarify the mechanism of action, we performed methylation-specific polymerase chain reaction, gelatin zymography, and western blot analysis.
Results:
The acyl-CoA synthetase inhibitor 2-fluoropalmitic acid (2-FPA) was selected as a candidate anti-glioma agent. 2-FPA suppressed the viability and stem-like phenotype of GSCs. It also inhibited proliferation and invasion of glioma cell lines. Combination therapy of 2-FPA with TMZ synergistically enhanced the efficacy of TMZ. 2-FPA suppressed the expression of phosphor-ERK, CD133, and SOX-2; reduced MMP-2 activity; and increased methylation of the MGMT promoter.
Conclusion:
2-FPA was identified as a potential therapeutic agent against GBM. To extend these findings, physiological studies are required to examine the efficacy of 2-FPA against GBM in vivo.
Insights
Researchers identified 2-fluoropalmitic acid (2-FPA) as a promising agent against glioblastoma (GBM). This compound overcomes temozolomide (TMZ) resistance and enhances GBM treatment efficacy, offering new hope for patients.
Area of Science:
- Neuro-oncology
- Cancer Therapeutics
- Drug Discovery
Background:
- Glioblastomas (GBMs) are aggressive brain tumors with limited treatment options.
- Temozolomide (TMZ) resistance is a major challenge in GBM therapy.
- Novel agents are needed to improve patient outcomes for GBM.
Purpose of the Study:
- To identify novel therapeutic agents for GBM through drug screening.
- To investigate the anti-glioma effects of a selected drug candidate.
- To evaluate combination therapy with TMZ for enhanced GBM treatment.
Main Methods:
- Screened 1,301 compounds against glioma stem cells (GSCs).
- Assessed drug effects on GSC viability, proliferation, sphere formation, and invasion.
- Performed combination therapy with TMZ and analyzed mechanisms including gene expression and enzyme activity.
Main Results:
- Selected 2-fluoropalmitic acid (2-FPA), an acyl-CoA synthetase inhibitor, as a potent anti-glioma agent.
- 2-FPA reduced GSC viability and stem-like properties, inhibited glioma cell proliferation and invasion.
- Combination of 2-FPA and TMZ synergistically enhanced TMZ's efficacy against GBM.
Conclusions:
- 2-Fluoropalmitic acid (2-FPA) shows significant potential as a therapeutic agent for glioblastoma.
- 2-FPA demonstrates efficacy in overcoming TMZ resistance and enhancing treatment.
- Further in vivo studies are warranted to confirm 2-FPA's therapeutic potential against GBM.
